NanoString Highlights Space Biology Research at the 2022 American Association of Cancer Research (AACR) Conference

SEATTLE–(BUSINESS WIRE)–NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced highlights of more than 125 reported studies possible by the NanoString platforms that will be presented at the American Association of Cancer Research (AACR) 2022 meeting, taking place April 8-13, 2022.

At AACR 2022, more than 110 posters and 15 oral presentations will showcase unique biological knowledge generated using NanoString Technologies’ platforms. This is the highest number of AACR abstracts in a single year for NanoString and demonstrates the growing adoption of space biology in cancer research. These abstracts include at least 36 studies exploring spatial biology using the CosMx™ Spatial Molecular Imager (SMI) and GeoMx® Digital Spatial Profiler (DSP), and 59 studies exploring gene expression using the CosMx™ Spatial Molecular Imager (SMI) and GeoMx® Digital Spatial Profiler (DSP) nCounter® analysis.

“NanoString customers continue to make tremendous contributions to our understanding of cancer and the development of treatments,” said Brad Gray, president and CEO of NanoString. “We are especially excited to highlight research studies that leverage our latest space biology product offerings. These include simultaneous detection of RNA and proteins on a single slide using GeoMx DSP and 100-plex protein imaging using the CosMx SMI.

Several studies and presentations featuring the use of NanoString’s space biology platforms are shown below.

Spotlight Theater, April 12, 10:00-11:00 CST

NanoString will host a spotlight theater during AACR on April 12 from 10:00 a.m. to 11:00 a.m. CST, featuring Joseph Beechem, Ph.D., Senior Vice President of R&D and Chief Scientific Officer of NanoString, presenting “Spatial Profiling of the Whole Transcriptome and High-Plex Single-Cell Imaging: Quantum Leaps in the Study of Cancer.“Arutha Kulasinghe, Ph.D., National Health and Medical Research Council (NHMRC) Researcher, Queensland University of Technology, will present”Spatial genomics in immunotherapy… and COVID-19.” And Hargita Kaplan, Director of Translational Medicine, Clinical Laboratory Operations, Atreca, Inc., will present “Collaboration with the TCR Alpha program of the GeoMx DSP WTA platform.”

Poster: Multi-omics dissection of immunotherapeutic response in groups of non-small cell lung cancer

Arutha Kulasinghe, Ph.D., NHMRC Research Fellow, Queensland University of Technology

This study used spatial transcriptomics methods, including GeoMx DSP and multiplex IHC, to define the tumour/stroma compartment-specific proteome and transcriptome of a cohort of 2n/a non-small cell lung cancer patients treated with online immunotherapy.

Poster: Development of a personalized breast cancer protein biomarker assay from the GeoMx high-plex digital spatial profiler

Christopher Corless, MD, Ph.D., Oregon Health and Science University

The objective of this study was to develop a high-plex assay to simultaneously quantify 27 established and novel breast cancer (BC)-related immune proteins and phosphoproteins using the GeoMx PSD. The performance of the custom test was compared to standard immunohistochemistry-based BC clinical biomarker tests (e.g., ER, PR, HER2) across all BC subtypes and multiple laboratories with statistically consistent agreement. significant.

Poster: A single-cell spatial multi-omics atlas and cellular interactome of all major skin cancers types

Quan Ngyuen, Ph.D., University of Queensland

Along with other multi-omics tools, CosMx SMI has been used to generate the first single cell spatial atlas and cell interactome of all major types of skin cancer (squamous cell carcinoma, basal cell carcinoma and melanoma). Spatial transcriptomics with CosMx SMI reveals cell type organization into distinct functional tissue layers and identifies cancer-, patient-, and region-specific differences in cell-cell interaction.

Poster: Subcellular characterization of more than 100 proteins in FFPE tumor biopsies with CosMx Spatial Molecular Imager

Zach Lewis, Ph.D., NanoString Technologies

108 proteins were imaged in a breast cancer biopsy using the CosMx Spatial Molecular Imager, representing one of the most complex protein imaging studies. CosMx coding and chemistry enables high-throughput, short-time protein imaging studies on the same instrument as the CosMx single-molecule RNA assay.

Poster: Multi-omics analysis of whole transcriptome and high plex protein assays on a single FFPE slide

Shilah Bonnet, Ph.D., NanoString Technologies NanoString Technologies

The new GeoMx Spatial Proteogenomic workflow enables co-detection of proteins (>100-plex) and RNA (up to 21,000-plex) from a single FFPE slide. The performance of the proteogenomics workflow has been confirmed on various cell pellets and tissue types.

Oral: AACR NextGen Star, Will Hwang, MD, PhD

April 11, 11:26 a.m. to 11:41 a.m. CST

As an AACR NextGen Star, Will Hwang, MD, Ph.D., radiation oncologist and researcher, Massachusetts General Hospital Cancer Center/Harvard Medical School, will present: “The multicellular spatial community exhibiting a novel neural-like malignant phenotype is enriched in pancreatic cancer after neoadjuvant chemotherapy and radiotherapy.”

About NanoString Technologies, Inc.

NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company offers three platforms that allow researchers to map the universe of biology. The nCounter® analysis system, cited in over 5,300 peer-reviewed publications, provides a way to easily profile the expression of hundreds of genes, proteins, miRNAs or copy number variations, simultaneously with sensitivity and high precision. NanoString’s GeoMx® Digital Spatial Profiler enables highly multiplexed spatial profiling of RNA and protein targets in various sample types, including FFPE tissue sections, and has been cited in over 100 peer-reviewed publications . The CosMx™ Spatial Molecular Imager, expected to be commercially available in 2022, enables highly sensitive, high-resolution imaging of hundreds to thousands of RNAs or proteins directly from single cells in morphologically intact whole tissue sections . For more information, visit http://www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, CosMx, GeoMx and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Comments are closed.